Login to Your Account

Hepatitis C combo data buoys Regulus Therapeutics' shares

By Michael Fitzhugh
Staff Writer

Wednesday, February 17, 2016

Interim data suggesting that the length of direct-acting antiviral (DAA) treatment regimens for many hepatitis C (HCV) cases could be halved by adding Regulus Therapeutics Inc.'s microRNA antagonist, RG-101, pushed company shares (NASDAQ:RGLS) 19.3 percent higher to $7.49 by Wednesday's market close.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription